Abstract Library

#4480 Efficacy of regional and systemic therapies for refractory hypoglycaemia in malignant insulinoma

Introduction: Insulinoma is a rare neuroendocrine tumour characterised by inappropriate autonomous insulin secretion.

Conference:

Presenting Author: Koch R

Authors: Koch R, McGarrah P, Eiring R, Hobday T, Halfdanarson T,

Keywords: Insulinoma, radioligand therapy,

#4370 Role of 68GA-DOTATOC pet/ct in therapeutic decision-making for well-differentiated neuroendocrine tumours

Introduction: 68Ga-DOTATOC PET/CT is a highly sensitive and specific test for assessing gastroenteropancreatic and pulmonary neuroendocrine tumours (NET) expressing somatostatin receptors.

Conference:

Presenting Author: Cruz-Diaz W

Authors: Cruz Diaz W, Landaeta Kancev L, Martinez-Amores Martínez B, Bastidas Tamayo J, Estrella Santos A,

Keywords: 68Ga-DOTATOC PET/CT, well-differentiated, gastroenteropancreatic, pulmonary, neuroendocrine tumour, Lu-177-DOTATATE,

#3417 SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imaging

Introduction: SARS-CoV-2 (COVID19) vaccinations have shown high efficacy. Therefore, increased chances exist that patients undergoing Peptide Receptor Radionuclide Therapy (PRRT) or radionuclide imaging for Neuroendocrine Tumors (NETs) may have being recently vaccinated.

Conference:

Presenting Author: Kolade O

Authors: Kolade O, Ayeni A, Brink A, Steyn R, Prasad V,

Keywords: COVID-19, SARS-CoV-2, Lu-177 DOTATATE, Ga-68 DOTANOC, Vaccination, PRRT, Neuroendocrine Tumor,

#3338 Utility of SSTR radioligands in imaging and treatment of paediatric GEP-NETs

Introduction: Metastasized gastroenteropancreatic neuroendocrine tumors (GEP-NETS) in paediatric patients

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Steyn R

Authors: Steyn R, Kolade O, Aldera A, Masoka B, Radebe B,

Keywords: SSTR, PRRT, paediatric, GEP-NET,

#3334 Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)

Introduction: The NETTER-1 trial formed the basis for standard practice of PRRT, consisting of 4 cycles with follow-up imaging during midtreatment and after completion to evaluate disease response. However, in clinical practice the timing of midpoint imaging varies if performed at all, and it is unclear how often it influences subsequent management.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Norman A, Wee C, Hobday T, Kendi A, Johnson G,

Keywords: midpoint imaging, PRRT, clinical decision making,